DSM profit dips 2% in Q1 2012
Nutrition and performance materials drive growth
DSM has reported net sales of close to €2.3bn for Q1 2012, down 2% on the prior year period. Operating profit before depreciation and amortisation meanwhile was €306m, a 12% dip on Q1 2011 profit (€348m). According to the company, its nutrition and performance materials businesses enjoyed profitable growth, while it’s pharma segment remained weak.
Commenting on the results, Feike Sijbesma, ceo and chairman of the DSM managing board, said: “In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012. DSM has successfully transformed itself into a Life Sciences and Materials Sciences company.”
